Navigation Links
Research Brings New Hope to Multiple Sclerosis Patients
Date:2/18/2009

Aurora St. Luke's Medical Center Discovers Way to Fight Rare, but Deadly, Side Effect from Drug.

MILWAUKEE, Feb. 18 /PRNewswire/ -- Researchers at Aurora St. Luke's Medical Center have developed a technique that counteracts an unusual, but serious, side effect from natalizumab (Tysabri(R)), a drug that fights multiple sclerosis (MS).

The side effect is a brain virus called progressive multifocal leukoencephalopathy (PML).

"This virus looks like a multiple sclerosis relapse," Dr. Bhupendra Khatri says. "It rapidly destroys the white matter of the brain. Now we know exactly how to respond if this virus emerges."

The response is a series of plasma exchanges that filter the drug out of the blood stream, allowing the immune system to recover and fight the virus.

Multiple sclerosis is a disease where the body's immune system attacks the protective sheath surrounding the nerves. Natalizumab suppresses the immune system to slow or halt the progression of the disease. However, if the patient contracts PML, the immune system is not strong enough to combat the infection, so the drug needs to be removed from the body quickly.

Dr. Khatri, medical director of Aurora's Regional MS Center is lead author of the study published in the Feb. 3 issue of Neurology, the official publication of the American Academy of Neurology.

In the study 12 multiple sclerosis patients on natalizumab underwent three plasma exchange sessions over a five-day or an eight-day period. By replacing the drug-infused plasma with clean fluid, Dr. Khatri and his team were able to get 92 percent of the drug out of patients' bodies over a span of eight days instead of the 12 weeks it would take with no treatment.

Debra Goodwin, a clinical research nurse who worked on the study and a multiple sclerosis patient herself, says the discovery gives new hope to those with the disease who take natalizumab.

"If something were to go wrong, now there is a demonstrated method to remove the drug from the body and help the patient fight PML," Goodwin says.

The National Multiple Sclerosis Society estimates 400,000 people in the United States have MS. There is no cure for multiple sclerosis though there are several drugs that can slow or stop its progress. Symptoms can include blurred vision, loss of coordination and short-term or long-term memory loss.

Aurora Health Care is a not-for-profit health care provider and a national leader in efforts to improve the quality of health care. Aurora offers care at sites in more than 90 communities throughout eastern Wisconsin.

Aurora's online newsroom: http://www.aurora.org/newsroom

The Regional MS Center: www.aurora.org/MS


'/>"/>
SOURCE Aurora St. Luke's Medical Center
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Study calls for increased research in flu transmission to prepare for pandemic flu outbreak
2. Research increases possibilities of personalizing treatment of infant osteosarcoma
3. Two Scientists Honored with MetLife Foundation Awards for Medical Research in Alzheimers Disease
4. The Canadian Foundation for Global Health Announces a Research and Development Partnership with Medizone International, Inc.
5. Apple's iPod Touch Joins the iPhone as a Stuttering Therapy Tool At Hollins Communications Research Institute
6. Rice Universitys Baker Institute experts available to discuss stem cell research, recommendations
7. eResearchTechnology, Inc. to Announce Fourth Quarter and Full Year 2008 Results on February 26, 2009
8. National Pharmaceutical Council on Economic Stimulus Package: Comparative Effectiveness Research Funding Should Target Improvements in Quality of Patient Care
9. OHSU vaccine research targets HIV in the slower, early stage of infection
10. American Association for Cancer Research lauds Senator Arlen Specter
11. In flurry of studies, researcher details role of apples in inhibiting breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2017)... Melbourne, Fla. (PRWEB) , ... July 23, 2017 ... ... Stern, M.D., has joined Florida Pain Relief Group – Melbourne, a practice owned ... to board certification in interventional pain management, Dr. Stern also is certified in ...
(Date:7/22/2017)... ... July 22, 2017 , ... ... irreparable rotator cuff repairs the opportunity to return to sports and jobs that ... Orthopaedic Society for Sports Medicine’s Annual Meeting in Toronto, Ontario, Canada. ...
(Date:7/21/2017)... ... July 21, 2017 , ... Roderick ... planning services to families and business owners in northern Florida, is joining the ... provide support to area adults with developmental challenges. , The First Coast YMCA ...
(Date:7/21/2017)... ... , ... Hospital M&A activity slowed in the second quarter of 2017, according ... to 23 in the second quarter, up 15% from the 20 publicly announced acquisitions ... in the year-ago second quarter. Only four of the transactions disclosed a purchase price ...
(Date:7/21/2017)... La. (PRWEB) , ... July 21, 2017 , ... ... allow 4th-year medical students improve their chances of acceptance to a residency in ... those who have earned degrees outside the U.S. , According to data released ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... , July 13, 2017  New York City-based market ... pharmaceutical markets should be aware of.  From new products to ... are detailed in a recently completed study, Potential Pipeline ... 1.  Age-Driven Growth - ... have been aware of the impact the growing population and, ...
(Date:7/11/2017)... WHIPPANY, N.J. , July 11, 2017  Bayer has ... across eight countries as part of its prestigious Bayer Hemophilia ... Children,s Hospital of Philadelphia and Uniformed ... are among the winners. Grant recipients were announced ... Thrombosis and Hemostasis (ISTH) 2017 Congress, Berlin, Germany ...
(Date:7/11/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... the development of oral drug delivery systems, announced today ... agreed to schedule an End-of-Phase II meeting with Oramed ... oral insulin capsule ORMD-0801 in the treatment of type ... secondary endpoints by indicating a statistically significant lowering of ...
Breaking Medicine Technology: